Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Mannkind Corporation

MNKD

MannKind Corp is a biopharmaceutical company dedicated to transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.

Last trade $4.06
Day change +$0.105 (+2.65%)
Day range $3.91 – $4.17
Volume 2,135,623
Market cap $1.27B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.27B
Price / earnings
—
Price / book
-34.18×
Price / sales
3.08×
EV / sales
4.16×
EV / EBITDA
143.7×

Profitability

Earnings per share
-$0.23
Return on assets
-10.35%
Return on equity
200.78%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-13.04×
Current ratio
2.22×
Quick ratio
1.77×
Cash ratio
0.38×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$78.41M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for MNKD, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$101.87M$109.37M$90.17M$111.96M$82.13M$76.53M$78.35M$76.78M
Cost of revenue$23.51M$29.54M$17.47M$29.67M$20.2M$20.57M$17.52M$19.6M
Gross profit$78.36M$79.83M$72.7M$82.28M$61.93M$55.96M$60.84M$57.17M
Selling, general and administrative$61.41M$58.3M$54.09M$58.41M$29.09M$31.62M$25.01M$23.97M
Research and development$14.36M$18M$17.23M$27.59M$14.06M$13.68M$11.02M$11.14M
Total operating expenses$80.93M$80.67M$75.68M$89.97M$43.15M$45.3M$36.04M$35.11M
Operating income-$2.57M-$836K-$2.99M-$7.69M$18.78M$10.66M$24.8M$22.06M
Interest expense-$10.58M-$14.82M-$12.43M-$13.87M-$7.33M-$6.19M-$10.63M-$7.48M
Income before taxes-$23.17M-$19.14M-$16.37M-$20.93M$7.78M$940K$13.62M$8.45M
Income taxes$51K-$106K$253K-$4.98M-$204K$272K$459K$1.02M
Net income-$23.22M-$19.03M-$16.62M-$15.95M$7.99M$668K$13.16M$7.42M
Net income attributable to common shareholders-$23.22M-$19.03M-$16.62M-$15.95M$7.99M$668K$13.16M$7.42M
EBITDA$4.66M$5.56M$3.4M-$1.66M$20.84M$12.75M$26.91M$24.22M
Basic earnings per share-$0.07-$0.06-$0.05-$0.05$0.03$0.00$0.04$0.03
Diluted earnings per share-$0.07-$0.06-$0.05-$0.05$0.03$0.00$0.04$0.03

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Compared to Estimates, MannKind (MNKD) Q3 Earnings: A Look at Key Metrics

MannKind reported Q3 2026 revenue of $101.87 million, up 24% year-over-year but missing the consensus estimate of $105.56 million by 3.5%. EPS of -$0.07 beat expectations of -$0.08 by 12.5%. Key revenue segments showed mixed results: commercial product sales surged 101.8% YoY but fell short of estimates, while Furoscix and Afrezza revenues underperformed analyst expectations. The stock has a Zacks Rank #3 (Hold) rating.

Zacks Investment Research

MannKind (MNKD) Reports Q3 Loss, Misses Revenue Estimates

MannKind (MNKD) reported a quarterly loss of $0.07 per share, beating consensus estimates of $0.08 loss by 12.5%, with revenues of $101.87 million missing estimates by 3.5%. The stock has declined 30.7% year-to-date versus the S&P 500's 12.3% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.

GlobeNewswire Inc.

MannKind to Participate in the Chardan Healthcare Conference

MannKind Corporation announced that CEO Michael Castagna will participate in a panel discussion on innovation in chronic respiratory diseases at the Chardan Healthcare Conference on October 20, 2026. The company will also conduct one-on-one investor meetings. MannKind is a biopharmaceutical company focused on cardiometabolic and orphan lung diseases, with treatments addressing diabetes, pulmonary hypertension, and fluid overload conditions.

GlobeNewswire Inc.

MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)

MannKind Corporation announced new clinical data for Furoscix ReadyFlow, an autoinjector delivering IV-equivalent diuretic therapy for heart failure and chronic kidney disease. Presented at the HFSA 2026 Annual Scientific Meeting, the data demonstrates comparable urine output to IV furosemide, consistent bioavailability across injection sites, and seamless transition capabilities from the previous On-body Infusor formulation. The product received FDA approval in July 2026 and is designed to enable earlier outpatient intervention for fluid overload management.

Zacks Investment Research

FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH

United Therapeutics announced FDA acceptance of its NDA for ralinepag, a once-daily oral prostacyclin receptor agonist for pulmonary arterial hypertension (PAH). The Phase III ADVANCE OUTCOMES study showed ralinepag reduced clinical worsening risk by 55% versus placebo and improved secondary endpoints. If approved in June 2027, it would be the first once-daily oral prostacyclin for PAH, complementing UTHR's existing PAH portfolio.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Mar 3, 20171-for-5reverse split